Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. Dupixent nears EU approval for rare ...

Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer ...

Prurigo nodularis is a serious skin condition characterized by several debilitating symptoms, including chronic itch, skin nodules covering large body areas, and poor sleep quality. 5-7,10 ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis and prurigo nodularis in patients with moderate-to-severe cases of the skin ...

This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024. 14 Atopic dermatitis is a common ...

7.3% of placebo reached IGA success by week 16. Nemolizumab monotherapy improved the signs and symptoms of prurigo nodularis, according to new data published in JAMA Dermatology. The newly ...

2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis 11-13 This positive opinion from the ...